|
6.11.2014 |
EN |
Official Journal of the European Union |
C 391/3 |
Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2013
2014/C 391/03
Subcommitee I on the free movement of goods
To be noted by the EEA Joint Committee
With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January - 30 June 2013, at their meeting on 4 April 2014:
|
Annex I |
List of new marketing authorisations |
|
Annex II |
List of renewed marketing authorisations |
|
Annex III |
List of extended marketing authorisations |
|
Annex IV |
List of withdrawn marketing authorisations |
|
Annex V |
List of suspended marketing authorisations |
ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2013:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/12/788/001-006 |
Seebri Breezhaler |
Liechtenstein |
30.4.2013 |
|
EU/1/12/789/001-006 |
Enurev Breezhaler |
Liechtenstein |
30.4.2013 |
|
EU/1/12/790/001-006 |
Tovanor Breezhaler |
Liechtenstein |
30.4.2013 |
|
EU/1/12/791/001 |
Glybera |
Liechtenstein |
30.4.2013 |
|
EU/1/12/795/001-010 |
Forxiga |
Liechtenstein |
30.4.2013 |
|
EU/1/12/797/001-002 |
Eylea |
Liechtenstein |
30.4.2013 |
|
EU/1/12/803/001-002 |
NexoBrid |
Liechtenstein |
30.4.2013 |
|
EU/1/12/803/001-002 |
NexoBrid |
Iceland |
14.1.2013 |
|
EU/1/12/803/001-002 |
NexoBrid |
Norway |
11.1.2013 |
|
EU/1/12/804/001-016 |
BindRen |
Liechtenstein |
30.4.2013 |
|
EU/1/12/804/001-016 |
BindRen |
Iceland |
8.2.2013 |
|
EU/1/12/804/001-016 |
BindRen |
Norway |
27.2.2013 |
|
EU/1/12/805 |
Amyvid |
Liechtenstein |
28.2.2013 |
|
EU/1/12/805/001-004 |
AMYViD |
Iceland |
6.2.2013 |
|
EU/1/12/805/001-004 |
AMYViD |
Norway |
4.2.2013 |
|
EU/1/12/806/001-005 |
Ryzodeg |
Liechtenstein |
28.2.2013 |
|
EU/1/12/806/001-005 |
Ryzodeg |
Iceland |
20.2.2013 |
|
EU/1/12/806/001-005 |
Ryzodeg |
Norway |
12.2.2013 |
|
EU/1/12/807/001-009 |
Tresiba |
Liechtenstein |
28.2.2013 |
|
EU/1/12/807/001-009 |
Tresiba |
Iceland |
20.2.2013 |
|
EU/1/12/807/001-009 |
Tresiba |
Norway |
12.2.2013 |
|
EU/1/12/808/001-040 |
Imatinib Teva |
Liechtenstein |
28.2.2013 |
|
EU/1/12/808/001-040 |
Imatinib Teva |
Iceland |
5.2.2013 |
|
EU/1/12/808/001-040 |
Imatinib Teva |
Norway |
22.1.2013 |
|
EU/1/12/809/001-014 |
Betmiga |
Liechtenstein |
28.2.2013 |
|
EU/1/12/809/001-014 |
Betmiga |
Iceland |
10.1.2013 |
|
EU/1/12/809/001-014 |
Betmiga |
Norway |
17.1.2013 |
|
EU/1/12/810 |
Krystexxa |
Liechtenstein |
30.4.2013 |
|
EU/1/12/810/001 |
Krystexxa |
Iceland |
14.1.2013 |
|
EU/1/12/810/001 |
Krystexxa |
Norway |
25.1.2013 |
|
EU/1/12/811/001-005 |
Lyxumia |
Iceland |
12.2.2013 |
|
EU/1/12/811/001-005 |
Lyxumia |
Norway |
12.2.2013 |
|
EU/1/12/812 |
Bexsero |
Liechtenstein |
28.2.2013 |
|
EU/1/12/812/001-004 |
Bexsero |
Iceland |
14.2.2013 |
|
EU/1/12/812/001-004 |
Bexsero |
Norway |
4.2.2013 |
|
EU/1/12/814 |
Zaltrap |
Liechtenstein |
28.2.2013 |
|
EU/1/12/814/001-003 |
Zaltrap |
Iceland |
12.2.2013 |
|
EU/1/12/814/001-003 |
Zaltrap |
Norway |
27.2.2013 |
|
EU/1/12/815/001-005 |
Selincro |
Liechtenstein |
30.4.2013 |
|
EU/1/12/815/001-005 |
Selincro |
Iceland |
19.3.2013 |
|
EU/1/12/815/001-005 |
Selincro |
Norway |
11.3.2013 |
|
EU/1/13/813/001 |
Perjeta |
Liechtenstein |
30.4.2013 |
|
EU/1/13/813/001 |
Perjeta |
Iceland |
20.3.2013 |
|
EU/1/13/813/001 |
Perjeta |
Norway |
9.4.2013 |
|
EU/1/13/817/001-041 |
Actelsar HCT |
Iceland |
21.3.2013 |
|
EU/1/13/817/001-041 |
Actelsar HCT |
Norway |
22.4.2013 |
|
EU/1/13/818/001-004 |
Bosulif |
Iceland |
15.4.2013 |
|
EU/1/13/818/001-004 |
Bosulif |
Norway |
30.4.2013 |
|
EU/1/13/819/001 |
JETREA |
Liechtenstein |
30.4.2013 |
|
EU/1/13/819/001 |
JETREA |
Iceland |
11.4.2013 |
|
EU/1/13/819/001 |
JETREA |
Norway |
22.3.2013 |
|
EU/1/13/820/001-026 |
Maruxa |
Liechtenstein |
30.6.2013 |
|
EU/1/13/820/001-026 |
Maruxa |
Norway |
24.5.2013 |
|
EU/1/13/821/001-030 |
Tolucombi |
Liechtenstein |
30.4.2013 |
|
EU/1/13/821/001-030 |
Tolucombi |
Iceland |
21.3.2013 |
|
EU/1/13/821/001-030 |
Tolucombi |
Norway |
22.3.2013 |
|
EU/1/13/823/001-002 |
Adasuve |
Norway |
12.3.2013 |
|
EU/1/13/823/001-002 |
Adasuve |
Liechtenstein |
30.4.2013 |
|
EU/1/13/823/001-002 |
Adasuve |
Iceland |
18.3.2013 |
|
EU/1/13/824 |
Nemdatine |
Liechtenstein |
30.4.2013 |
|
EU/1/13/824/001-020 |
Nemdatine |
Iceland |
21.5.2013 |
|
EU/1/13/824/001-020 |
Nemdatine |
Norway |
3.5.2013 |
|
EU/1/13/825 |
Imatinib Actavis |
Liechtenstein |
30.6.2013 |
|
EU/1/13/825/001-018 |
Imatinib Actavis |
Iceland |
16.5.2013 |
|
EU/1/13/825/001-018 |
Imatinib Actavis |
Norway |
20.6.2013 |
|
EU/1/13/826 |
Memantine LEK |
Liechtenstein |
30.4.2013 |
|
EU/1/13/826/001-011 |
Memantine LEK |
Iceland |
21.5.2013 |
|
EU/1/13/826/001-011 |
Memantine LEK |
Norway |
3.5.2013 |
|
EU/1/13/827 |
Memantine Mylan |
Liechtenstein |
30.4.2013 |
|
EU/1/13/827/001-036 |
Memantine Mylan |
Iceland |
21.5.2013 |
|
EU/1/13/827/001-036 |
Memantine Mylan |
Norway |
3.5.2013 |
|
EU/1/13/828 |
Hexacima |
Liechtenstein |
30.4.2013 |
|
EU/1/13/828/001-007 |
Hexacima |
Iceland |
17.5.2013 |
|
EU/1/13/828/001-007 |
Hexacima |
Norway |
15.5.2013 |
|
EU/1/13/829 |
Hexyon |
Liechtenstein |
30.4.2013 |
|
EU/1/13/829/001-007 |
Hexyon |
Iceland |
17.5.2013 |
|
EU/1/13/829/001-007 |
Hexyon |
Norway |
15.5.2013 |
|
EU/1/13/830/001-002 |
Stribild |
Iceland |
19.6.2013 |
|
EU/1/13/830/001-002 |
Stribild |
Norway |
24.5.2013 |
|
EU/1/13/835/001-018 |
Voriconazole Accord |
Iceland |
31.5.2013 |
|
EU/1/13/835/001-018 |
Voriconazole Accord |
Norway |
31.5.2013 |
|
EU/1/13/836 |
Memantine ratiopharm |
Liechtenstein |
30.6.2013 |
|
EU/1/13/836/001-023 |
Memantine ratiopharm |
Norway |
25.6.2013 |
|
EU/1/13/840/001-005 |
HyQvia |
Iceland |
27.5.2013 |
|
EU/1/13/840/001-005 |
HyQvia |
Norway |
3.6.2013 |
|
EU/2/12/142/001-006 |
Cardalis |
Norway |
20.6.2013 |
|
EU/2/12/144/001-004 |
Contacera |
Liechtenstein |
28.2.2013 |
|
EU/2/12/144/001-004 |
Contacera |
Iceland |
3.1.2013 |
|
EU/2/12/144/001-004 |
Contacera |
Norway |
17.1.2013 |
|
EU/2/12/145/001-003 |
Kexxtone |
Liechtenstein |
30.4.2013 |
|
EU/2/12/145/001-003 |
Kexxtone |
Iceland |
27.2.2013 |
|
EU/2/12/145/001-003 |
Kexxtone |
Norway |
8.3.2013 |
|
EU/2/12/146/001 |
Semintra |
Liechtenstein |
30.4.2013 |
|
EU/2/12/146/001 |
Semintra |
Iceland |
12.3.2013 |
|
EU/2/12/146/001 |
Semintra |
Norway |
5.4.2013 |
|
EU/2/12/147/001-004 |
Pexion |
Liechtenstein |
30.4.2013 |
|
EU/2/12/147/001-004 |
Pexion |
Iceland |
19.3.2013 |
|
EU/2/12/147/001-004 |
Pexion |
Norway |
8.3.2013 |
|
EU/2/13/148 |
Meloxidolor |
Liechtenstein |
30.6.2013 |
|
EU/2/13/148/001-007 |
Meloxidolor |
Iceland |
21.5.2013 |
|
EU/2/13/148/001-007 |
Meloxidolor |
Norway |
22.4.2013 |
|
EU/2/13/149 |
ECOPORC SHIGA |
Liechtenstein |
30.4.2013 |
|
EU/2/13/149/001-002 |
ECOPORC SHIGA |
Iceland |
15.5.2013 |
|
EU/2/13/149/001-002 |
ECOPORC SHIGA |
Norway |
13.5.2013 |
|
EU/2/13/150 |
Oncept IL-2 |
Liechtenstein |
30.6.2013 |
|
EU/2/13/151/001-003 |
Equilis West Nile |
Iceland |
27.6.2013 |
ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2013:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/03/247 |
Forsteo |
Liechtenstein |
30.4.2013 |
|
EU/1/03/247/001-002 |
Forsteo |
Iceland |
19.2.2013 |
|
EU/1/03/247/001-002 |
Forsteo |
Norway |
6.3.2013 |
|
EU/1/07/423 |
Vectibix |
Liechtenstein |
30.4.2013 |
|
EU/1/07/423/001-003 |
Vectibix |
Iceland |
5.2.2013 |
|
EU/1/07/423/001-003 |
Vectibix |
Norway |
12.2.2013 |
|
EU/1/07/428/001 |
Abraxane |
Liechtenstein |
30.4.2013 |
|
EU/1/07/428/001 |
Abraxane |
Iceland |
5.2.2013 |
|
EU/1/07/428/001 |
Abraxane |
Norway |
11.2.2013 |
|
EU/1/07/430/001-002 |
Atripla |
Liechtenstein |
30.4.2013 |
|
EU/1/07/433/001 |
Nevanac |
Iceland |
9.1.2013 |
|
EU/1/07/434 |
Avamys |
Liechtenstein |
28.2.2013 |
|
EU/1/07/434/001-003 |
Avamys |
Iceland |
11.1.2013 |
|
EU/1/07/434/001-003 |
Avamys |
Norway |
14.1.2013 |
|
EU/1/07/435/001-018 |
Tesavel |
Liechtenstein |
30.4.2013 |
|
EU/1/07/438/001-006 |
Myfenax |
Liechtenstein |
30.4.2013 |
|
EU/1/07/439/001-006 |
Mycophenolate mofetil Teva |
Liechtenstein |
30.4.2013 |
|
EU/1/07/440 |
Tyverb |
Liechtenstein |
30.4.2013 |
|
EU/1/07/440/001-007 |
Tyverb |
Norway |
15.5.2013 |
|
EU/1/08/441 |
Effentora |
Liechtenstein |
30.4.2013 |
|
EU/1/08/441/001-010 |
Effentora |
Iceland |
20.3.2013 |
|
EU/1/08/441/001-010 |
Effentora |
Norway |
12.3.2013 |
|
EU/1/08/442/001-019 |
Pradaxa |
Norway |
26.2.2013 |
|
EU/1/08/442/001-019 |
Pradaxa |
Liechtenstein |
30.4.2013 |
|
EU/1/08/442/001-019 |
Pradaxa |
Iceland |
15.2.2013 |
|
EU/1/08/443/001 |
Thalidomide Celgene |
Iceland |
14.1.2013 |
|
EU/1/08/443/001 |
Thalidomide Celgene |
Norway |
16.1.2013 |
|
EU/1/08/446/001-006 |
Privigen |
Iceland |
22.3.2013 |
|
EU/1/08/446/001-006 |
Privigen |
Norway |
21.3.2013 |
|
EU/1/08/447/001-012 |
Adenuric |
Norway |
15.1.2013 |
|
EU/1/08/447/001-012 |
Adenuric |
Liechtenstein |
30.4.2013 |
|
EU/1/08/447/001-012 |
Adenuric |
Iceland |
14.1.2013 |
|
EU/1/08/448/001-002 |
Mycamine |
Liechtenstein |
30.4.2013 |
|
EU/1/08/448/001-002 |
Mycamine |
Iceland |
24.1.2013 |
|
EU/1/08/448/001-002 |
Mycamine |
Norway |
12.2.2013 |
|
EU/1/08/451 |
Volibris |
Liechtenstein |
30.4.2013 |
|
EU/1/08/451/001-004 |
Volibris |
Iceland |
5.2.2013 |
|
EU/1/08/451/001-004 |
Volibris |
Norway |
12.2.2013 |
|
EU/1/08/453 |
Prepandrix |
Liechtenstein |
30.4.2013 |
|
EU/1/08/453/002 |
Prepandrix |
Iceland |
6.2.2013 |
|
EU/1/08/453/002 |
Prepandrix |
Norway |
4.2.2013 |
|
EU/1/08/454/001-002, 005-007 |
Extavia |
Iceland |
9.1.2013 |
|
EU/1/08/454/001-002, 005-007 |
Extavia |
Liechtenstein |
30.4.2013 |
|
EU/1/08/454/001-002, 005-007 |
Extavia |
Norway |
10.1.2013 |
|
EU/1/08/455 |
Janumet |
Liechtenstein |
30.4.2013 |
|
EU/1/08/455/001-006 |
Janumet |
Norway |
10.4.2013 |
|
EU/1/08/455/001-016 |
Janumet |
Iceland |
25.3.2013 |
|
EU/1/08/456 |
Velmetia |
Liechtenstein |
30.4.2013 |
|
EU/1/08/456/001-016 |
Velmetia |
Iceland |
26.3.2013 |
|
EU/1/08/457 |
Efficib |
Liechtenstein |
30.4.2013 |
|
EU/1/08/457/001-016 |
Efficib |
Iceland |
26.3.2013 |
|
EU/1/08/461 |
Firazyr |
Liechtenstein |
30.4.2013 |
|
EU/1/08/461/001-002 |
Firazyr |
Iceland |
11.4.2013 |
|
EU/1/08/461/001-002 |
Firazyr |
Norway |
10.4.2013 |
|
EU/1/08/462 |
Ranexa |
Liechtenstein |
30.4.2013 |
|
EU/1/08/462/001-002 |
Ranexa |
Norway |
9.4.2013 |
|
EU/1/08/462/001-012 |
Ranexa |
Iceland |
20.3.2013 |
|
EU/1/08/463 |
Relistor |
Liechtenstein |
30.6.2013 |
|
EU/1/08/463/001-011 |
Relistor |
Iceland |
21.6.2013 |
|
EU/1/08/463/001-011 |
Relistor |
Norway |
26.6.2013 |
|
EU/1/08/465 |
Clopidogrel Zentiva |
Liechtenstein |
28.2.2013 |
|
EU/1/08/465/001-021 |
Clopidogrel Zentiva |
Iceland |
3.1.2013 |
|
EU/1/08/465/001-021 |
Clopidogrel Zentiva |
Norway |
5.2.2013 |
|
EU/1/08/467 |
Doribax |
Liechtenstein |
30.6.2013 |
|
EU/1/08/467/001-002 |
Doribax |
Iceland |
17.5.2013 |
|
EU/1/08/469 |
Oprymea |
Liechtenstein |
30.4.2013 |
|
EU/1/08/469/001-025 |
Oprymea |
Iceland |
14.5.2013 |
|
EU/1/08/469/001-025 |
Oprymea |
Norway |
24.5.2013 |
|
EU/1/08/472 |
Xarelto |
Liechtenstein |
30.6.2013 |
|
EU/1/08/472/001-033 |
Xarelto |
Norway |
13.6.2013 |
|
EU/1/08/472/001-033 |
Xarelto |
Iceland |
20.6.2013 |
|
EU/1/08/475 |
Olanzapine Mylan |
Liechtenstein |
30.6.2013 |
|
EU/1/08/475/001-060 |
Olanzapine Mylan |
Iceland |
20.6.2013 |
|
EU/1/08/475/001-060 |
Olanzapine Mylan |
Norway |
7.6.2013 |
|
EU/1/08/476 |
Adcirca |
Liechtenstein |
30.6.2013 |
|
EU/1/08/476/005-006 |
Adcirca |
Iceland |
31.5.2013 |
|
EU/1/08/476/005-006 |
Adcirca |
Norway |
4.6.2013 |
|
EU/1/10/625 |
Arzerra |
Liechtenstein |
30.4.2013 |
|
EU/1/10/625/001, 003 |
Arzerra |
Iceland |
15.3.2013 |
|
EU/1/10/625/001, 003 |
Arzerra |
Norway |
9.4.2013 |
|
EU/1/11/749 |
Caprelsa |
Liechtenstein |
30.4.2013 |
|
EU/1/11/749/001-002 |
Caprelsa |
Iceland |
12.3.2013 |
|
EU/1/11/749/001-002 |
Caprelsa |
Norway |
9.4.2013 |
|
EU/1/12/764 |
Pixuvri |
Liechtenstein |
30.4.2013 |
|
EU/1/12/764/001 |
Pixuvri |
Iceland |
12.4.2013 |
|
EU/1/12/764/001 |
Pixuvri |
Norway |
9.4.2013 |
|
EU/1/97/055/001-009 |
Viramune |
Liechtenstein |
30.4.2013 |
|
EU/1/97/055/001-009 |
Viramune |
Iceland |
14.1.2013 |
|
EU/1/97/055/001-009 |
Viramune |
Norway |
22.1.2013 |
|
EU/2/02/032/001-002 |
Vaxxitec HVT+IBD |
Norway |
11.6.2013 |
|
EU/2/03/037 |
ProteqFlu |
Liechtenstein |
30.4.2013 |
|
EU/2/03/037/005 |
ProteqFlu |
Iceland |
21.3.2013 |
|
EU/2/03/037/005 |
ProteqFlu |
Norway |
20.6.2013 |
|
EU/2/03/038 |
ProteqFlu-Te |
Liechtenstein |
30.4.2013 |
|
EU/2/03/038/005 |
ProteqFlu-Te |
Iceland |
21.3.2013 |
|
EU/2/03/038/005 |
ProteqFlu-Te |
Norway |
20.6.2013 |
|
EU/2/03/039 |
Advocate |
Liechtenstein |
28.2.2013 |
|
EU/2/03/039/001-054 |
Advocate |
Iceland |
19.2.2013 |
|
EU/2/03/039/001-054 |
Advocate |
Norway |
5.3.2013 |
|
EU/2/07/074/001-006 |
Prilactone |
Norway |
11.6.2013 |
|
EU/2/07/077/001-005 |
Meloxivet |
Norway |
5.4.2013 |
|
EU/2/07/078 |
Rheumocam |
Liechtenstein |
28.2.2013 |
|
EU/2/07/078/001-020 |
Rheumocam |
Iceland |
11.1.2013 |
|
EU/2/07/078/001-020 |
Rheumocam |
Norway |
21.1.2013 |
|
EU/2/07/079 |
Ingelvac CircoFLEX |
Liechtenstein |
30.4.2013 |
|
EU/2/07/079/001-008 |
Ingelvac CircoFLEX |
Iceland |
7.2.2013 |
|
EU/2/07/079/001-008 |
Ingelvac CircoFLEX |
Norway |
5.3.2013 |
|
EU/2/08/081/001-003 |
Posatex |
Iceland |
14.6.2013 |
|
EU/2/08/081/001-003 |
Posatex |
Norway |
11.6.2013 |
|
EU/2/08/083/001-005 |
Equioxx |
Iceland |
28.6.2013 |
|
EU/2/08/083/001-005 |
Equioxx |
Norway |
20.6.2013 |
ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2013:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/01/200/003-009 |
Viread |
Norway |
11.1.2013 |
|
EU/1/02/221/017 |
Pegasys |
Iceland |
26.3.2013 |
|
EU/1/02/221/017 |
Pegasys |
Norway |
26.3.2013 |
|
EU/1/06/380/006-007 |
Prezista |
Liechtenstein |
28.2.2013 |
|
EU/1/06/380/007 |
Prezista |
Iceland |
6.2.2013 |
|
EU/1/06/380/007 |
Prezista |
Norway |
11.2.2013 |
|
EU/1/07/433/002 |
Nevanac |
Norway |
24.5.2013 |
|
EU/1/07/436/003-004 |
Isentress |
Iceland |
19.3.2013 |
|
EU/1/07/436/003-004 |
Isentress |
Norway |
25.2.2013 |
|
EU/1/08/468/003 |
Intelence |
Norway |
17.4.2013 |
|
EU/1/09/538/009-010 |
Afinitor |
Iceland |
5.2.2013 |
|
EU/1/09/538/009-010 |
Afinitor |
Norway |
16.1.2013 |
|
EU/1/09/576/041-042 |
Irbesartan Teva |
Liechtenstein |
28.2.2013 |
|
EU/1/11/690/003-004 |
Zoely |
Liechtenstein |
28.2.2013 |
|
EU/1/11/693/017-024 |
Rivastigmine Actavis |
Iceland |
17.5.2013 |
|
EU/1/11/693/017-024 |
Rivastigmine Actavis |
Norway |
25.6.2013 |
|
EU/1/12/750/002 |
Esmya |
Liechtenstein |
28.2.2013 |
|
EU/1/12/770/005 |
Docetaxel Kabi |
Liechtenstein |
28.2.2013 |
|
EU/1/98/066/027-030 |
Exelon |
Iceland |
7.2.2013 |
|
EU/1/98/066/027-030 |
Exelon |
Norway |
12.2.2013 |
|
EU/1/98/077/020-023 |
Viagra |
Iceland |
17.5.2013 |
|
EU/1/98/077/020-023 |
Viagra |
Norway |
15.5.2013 |
|
EU/100/146/033-037 |
Keppra |
Liechtenstein |
28.2.2013 |
|
EU/2/08/090/029-031 |
Loxicom |
Iceland |
21.3.2013 |
|
EU/2/08/090/029-031 |
Loxicom |
Norway |
6.3.2013 |
|
EU/2/10/115/016-019 |
Comfortis |
Iceland |
8.2.2013 |
|
EU/2/10/115/016-019 |
Comfortis |
Norway |
14.1.2013 |
|
EU/2/11/134/018-020 |
Inflacam |
Norway |
17.1.2013 |
ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2013:
|
EU-Number |
Product |
Country |
Date of withdrawal |
|
EU/1/03/266 |
Bondenza |
Liechtenstein |
30.4.2013 |
|
EU/1/03/266/001-006 |
Bondenza |
Norway |
12.6.2013 |
|
EU/1/07/409 |
Riprazo |
Liechtenstein |
30.4.2013 |
|
EU/1/07/409/001-040 |
Riprazo |
Iceland |
27.5.2013 |
|
EU/1/07/409/001-040 |
Riprazo |
Norway |
14.3.2013 |
|
EU/1/08/458/001-014 |
Trevaclyn |
Iceland |
15.5.2013 |
|
EU/1/08/458/001-014 |
Trevaclyn |
Norway |
23.4.2013 |
|
EU/1/08/459/001-014 |
Tredaptive |
Iceland |
15.5.2013 |
|
EU/1/08/459/001-014 |
Tredaptive |
Norway |
23.4.2013 |
|
EU/1/08/460/001-014 |
Pelzont |
Iceland |
15.5.2013 |
|
EU/1/08/460/001-014 |
Pelzont |
Norway |
23.4.2013 |
|
EU/1/08/474/001-003 |
Alisade |
Iceland |
27.6.2013 |
|
EU/1/09/582/001 |
Rilonacept Regeneron |
Liechtenstein |
28.2.2013 |
|
EU/1/09/582/001 |
Rilonacept Regeneron |
Norway |
8.2.2013 |
|
EU/1/10/656/001-006 |
Possia |
Iceland |
15.4.2013 |
|
EU/1/10/656/001-006 |
Possia |
Norway |
12.6.2013 |
|
EU/1/11/683/001-080 |
Sprimeo HCT |
Norway |
21.3.2013 |
|
EU/1/12/754/001-021 |
Sepioglin |
Norway |
20.6.2013 |
|
EU/1/97/040/001-002 |
Teslascan |
Liechtenstein |
28.2.2013 |
|
EU/2/04/046 |
Nobivac Piro |
Liechtenstein |
30.6.2013 |
|
EU/2/04/046/001-003 |
Nobivac Piro |
Iceland |
3.6.2013 |
|
EU/2/04/046/001-003 |
Nobivac Piro |
Norway |
22.5.2013 |
ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2013:
|
EU-Number |
Product |
Country |
Date of suspension |
|
EU/1/09/509/001-004 |
Ribavirin Teva |
Norway |
3.1.2013 |
|
EU/1/09/527/001-006 |
Ribavirin Teva Pharma BV |
Norway |
3.1.2013 |